/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Virax Biolabs Group Ltd share price today is $0.196, up -3.59%. The stock opened at $0.202 against the previous close of $0.2033, with an intraday high of $0.202 and low of $0.1894.

style

pb-0

Virax Biolabs Group Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.196 -0.0359(-3.59%) VRAX at 13 Mar 2026 03:48 PM Biotechnology

Lowest Today 0.1894

Highest Today 0.202

Today’s Open 0.202

Prev. Close 0.2033

52 Week High 1.43

52 Week Low 0.19

Day’s Range: Low 0.1894 High 0.202

52-Week Range: Low 0.19 High 1.43

Virax Biolabs Group Ltd Institutional Holdings

Virax Biolabs Group Ltd Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Virax Biolabs Group Ltd Fundamentals

Market Cap 2.85 M

PB Ratio 0.2841

PE Ratio 0.0

Enterprise Value -1.30 M

Total Assets 6.43 M

Volume 207461

Virax Biolabs Group Ltd Company Financials

Annual Revenue FY25:6331 0.0M, FY24:156419 0.2M, FY23:8561 0.0M, FY22:0 0.0M, FY21:123820 0.1M

Annual Profit FY25:-53067 -0.1M, FY24:50590 0.1M, FY23:-1365 -0.0M, FY22:0 0.0M, FY21:-9434 -0.0M

Annual Net worth FY25:-6061247 -6.1M, FY24:-6733537 -6.7M, FY23:-5167028 -5.2M, FY22:-1708827 -1.7M, FY21:-679627 -0.7M

Quarterly Revenue Q3/2025:1608 0.0M, Q2/2025:1378 0.0M, Q2/2024:79919 0.1M, Q3/2023:76500 0.1M, Q1/2023:24969 0.0M

Quarterly Profit Q3/2025:-215414 -0.2M, Q2/2025:-46593 -0.0M, Q2/2024:40072 0.0M, Q3/2023:10518 0.0M, Q1/2023:11437 0.0M

Quarterly Net worth Q3/2025:-2338771 -2.3M, Q2/2025:-3304820 -3.3M, Q2/2024:-3823885 -3.8M, Q3/2023:-2909652 -2.9M, Q1/2023:-427207 -0.4M

About Virax Biolabs Group Ltd & investment objective

Company Information Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.

Organisation Biotechnology

Employees 19

Industry Biotechnology

CEO Mr. James Foster

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*